0.00

100.00% -123.96

Nuvalent Inc (NUVL)

Overview News Price History Option Chain Financials Why NUVL Down? Discussions Forecast

Nuvalent Inc stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month. Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Previous Close:

$123.96

Open:

24h Volume:

Relative Volume:

0.00

Market Cap:

$9.81B

Revenue:

Net Income/Loss:

$-450.07M

P/E Ratio:

0.00

EPS:

-6.0583

Net Cash Flow:

$-312.79M

1W Performance:

-100.00%

1M Performance:

-100.00%

6M Performance:

-100.00%

1Y Performance:

-100.00%

1-Day Range:

$0.00

1-Week Range:

$0.00

52-Week Range:

$0.00

$123.99

Nuvalent Inc Stock (NUVL) Company Profile

Name

Nuvalent Inc

Sector

Healthcare (1068)

Industry

Biotechnology (598)

Phone

508-446-2272

Address

ONE BROADWAY, 14TH FLOOR, CAMBRIDGE

Employee

228

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

NUVL's Discussions on Twitter

Compare NUVL vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NUVL Nuvalent Inc	0.00	9.81B	0	-450.07M	-312.79M	-6.0583
VRTX Vertex Pharmaceuticals Inc	519.51	130.64B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	793.74	80.46B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	990.54	61.58B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	146.69	57.48B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	205.11	43.68B	742.00K	-1.37B	-1.07B	-7.0731

Nuvalent Inc Stock (NUVL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-24-26	Downgrade	Bernstein	Outperform → Mkt Perform
May-22-26	Initiated	Bernstein	Outperform
Mar-30-26	Initiated	Wells Fargo	Overweight
Nov-24-25	Initiated	Truist	Buy
Nov-12-25	Initiated	Canaccord Genuity	Buy
Oct-16-25	Resumed	Stifel	Buy
Oct-15-25	Initiated	Cantor Fitzgerald	Overweight
Sep-04-25	Resumed	Guggenheim	Buy
Sep-03-25	Initiated	Raymond James	Outperform
Aug-19-25	Initiated	Piper Sandler	Overweight
Mar-14-25	Upgrade	UBS	Neutral → Buy
Dec-30-24	Initiated	H.C. Wainwright	Buy
Oct-24-24	Initiated	UBS	Neutral
Aug-29-24	Initiated	Barclays	Overweight
Apr-17-24	Initiated	Jefferies	Buy
Apr-01-24	Upgrade	Leerink Partners	Market Perform → Outperform
Feb-28-24	Resumed	Guggenheim	Buy
Feb-23-24	Initiated	Robert W. Baird	Outperform
Sep-27-23	Initiated	Stifel	Buy
Aug-08-23	Initiated	SVB Securities	Market Perform
Jul-24-23	Initiated	Guggenheim	Buy
Jan-18-23	Initiated	Wedbush	Outperform
Jun-24-22	Initiated	BMO Capital Markets	Outperform

View All

Nuvalent Inc Stock (NUVL) Latest News

Sep 12, 2026

NUVL Stock Surges 39% Premarket – Why Is GSK Buying This Boston-Based Oncology Company? - Stocktwits

Sep 12, 2026

Sep 08, 2026

GSK to Raise $6.5 Billion From US Debt Sale to Fund Nuvalent Acquisition - marketscreener.com

Sep 08, 2026

GSK to Raise $6.5 Billion From US Debt Sale to Fund Nuvalent Acquisition, Bloomberg Reports - marketscreener.com

Sep 08, 2026

GSK Commences Six-Part Dollar Bond Sale to Help Fund Nuvalent Acquisition - marketscreener.com

Sep 08, 2026

GSK Launches Six-Part Dollar Bond Sale to Support Nuvalent Acquisition Financing, Bloomberg Reports - marketscreener.com

Sep 08, 2026

Sep 07, 2026